DANAHER CORPORATION's ticker is DHR and the CUSIP is 235851102. A total of 2,042 filers reported holding DANAHER CORPORATION in Q3 2023. The put-call ratio across all filers is 0.89 and the average weighting 0.6%.
About DANAHER CORPORATION
Danaher Corporation is a global science and technology company that designs, manufactures, and markets innovative products and services to professional, medical, industrial, and commercial customers. The company operates through four segments: Life Sciences, Diagnostics, Dental, and Environmental & Applied Solutions.
Danaher's Life Sciences segment provides a range of research tools to scientists around the world, including mass spectrometry, chromatography, and automation systems. The Diagnostics segment offers a broad range of diagnostic products, including clinical chemistry, immunoassay, microbiology, and molecular diagnostic systems. The Dental segment provides a range of dental equipment and consumables, including imaging systems, dental instruments, and consumables. The Environmental & Applied Solutions segment offers a range of products and services to help customers protect the environment and improve productivity.
Danaher has a strong track record of growth and innovation, driven by its focus on continuous improvement and customer satisfaction. The company has a culture of operational excellence, which has enabled it to consistently deliver high-quality products and services to its customers. Danaher's management team is highly experienced and has a proven track record of creating value for shareholders.
In conclusion, Danaher Corporation is a well-established and innovative company that is well-positioned to continue delivering strong growth and value to its shareholders. With its focus on operational excellence and customer satisfaction, Danaher is a company that investors should keep an eye on.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $1,467,949,724 | +5.6% | 5,916,883 | +2.1% | 0.29% | +9.0% |
Q2 2023 | $1,390,282,437 | +14.2% | 5,793,111 | +20.0% | 0.27% | +6.0% |
Q1 2023 | $1,216,992,093 | +4.8% | 4,828,762 | +10.4% | 0.25% | +2.0% |
Q4 2022 | $1,160,975,721 | +21.7% | 4,374,082 | +18.4% | 0.25% | +15.4% |
Q3 2022 | $954,357,000 | +1.8% | 3,694,905 | -0.0% | 0.21% | +7.5% |
Q2 2022 | $937,046,000 | -5.5% | 3,696,143 | +9.3% | 0.20% | +16.4% |
Q1 2022 | $991,554,000 | -8.0% | 3,380,336 | +3.2% | 0.17% | 0.0% |
Q4 2021 | $1,078,077,000 | +8.0% | 3,276,731 | -0.0% | 0.17% | +0.6% |
Q3 2021 | $997,933,000 | +10.4% | 3,277,929 | -2.6% | 0.17% | +10.4% |
Q2 2021 | $903,580,000 | +31.9% | 3,367,046 | +10.6% | 0.15% | +21.3% |
Q1 2021 | $685,048,000 | +4.4% | 3,043,574 | +3.0% | 0.13% | +0.8% |
Q4 2020 | $656,316,000 | -0.6% | 2,954,517 | -3.6% | 0.13% | -12.5% |
Q3 2020 | $660,121,000 | +11.9% | 3,065,626 | -8.1% | 0.14% | +0.7% |
Q2 2020 | $589,858,000 | +36.2% | 3,335,733 | +6.6% | 0.14% | +13.5% |
Q1 2020 | $433,238,000 | -3.3% | 3,130,106 | +7.2% | 0.13% | +26.0% |
Q4 2019 | $448,109,000 | -21.6% | 2,919,660 | -26.2% | 0.10% | -27.5% |
Q3 2019 | $571,537,000 | +1.2% | 3,957,188 | +0.1% | 0.14% | +3.8% |
Q2 2019 | $564,881,000 | +8.4% | 3,952,428 | +0.1% | 0.13% | +5.6% |
Q1 2019 | $521,128,000 | +461.1% | 3,947,338 | +294.7% | 0.13% | +384.6% |
Q4 2015 | $92,880,000 | -10.7% | 1,000,000 | -18.0% | 0.03% | -16.1% |
Q3 2015 | $103,956,000 | -0.5% | 1,220,000 | -0.0% | 0.03% | +10.7% |
Q2 2015 | $104,432,000 | +0.8% | 1,220,137 | +0.0% | 0.03% | 0.0% |
Q1 2015 | $103,578,000 | -0.9% | 1,220,000 | 0.0% | 0.03% | 0.0% |
Q4 2014 | $104,566,000 | +12.8% | 1,220,000 | 0.0% | 0.03% | +7.7% |
Q3 2014 | $92,696,000 | -3.5% | 1,220,000 | 0.0% | 0.03% | 0.0% |
Q2 2014 | $96,051,000 | +5.0% | 1,220,000 | 0.0% | 0.03% | 0.0% |
Q1 2014 | $91,500,000 | -2.8% | 1,220,000 | 0.0% | 0.03% | 0.0% |
Q4 2013 | $94,184,000 | +11.4% | 1,220,000 | 0.0% | 0.03% | 0.0% |
Q3 2013 | $84,570,000 | +9.5% | 1,220,000 | 0.0% | 0.03% | +4.0% |
Q2 2013 | $77,226,000 | – | 1,220,000 | – | 0.02% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
ARTHUR M. COHEN & ASSOCIATES, LLC | 217,436 | $53,823,432 | 13.80% |
Defender Capital, LLC. | 152,962 | $37,949,802 | 13.74% |
Bancreek Capital Management, LP | 60,890 | $15,106,809 | 13.58% |
BOONE CAPITAL MANAGEMENT LLC | 129,163 | $32,045,340 | 10.11% |
Eagle Health Investments LP | 175,085 | $43,438,589 | 9.57% |
Third Point | 2,450,000 | $607,845,000 | 9.22% |
Clio Asset Management LLC | 41,695 | $10,344,530 | 9.04% |
Consulta Ltd | 500,000 | $124,050,000 | 8.91% |
Riverstone Advisors, LLC | 47,960 | $11,799,701 | 8.16% |
CADEN CAPITAL PARTNERS, LP | 123,755 | $27,215,377 | 7.66% |